Opticyte Amniotic Matrix, a product of biotechnology pioneer Merakris Therapeutics, based in Research Triangle Park, North Carolina, is a leader in researching, developing, and marketing regenerative ocular care products. We are pioneering commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Our vision is to improve global patient care and outcomes through the pioneering and innovation of cellular regenerative biotechnologies.
Merakris Therapeutics strives to:
• Be a leader in the research and development of regenerative medicine.
• Deliver effective medical therapies that require fewer treatments and help to improve patient outcomes, while reducing the overall cost of care.
• Educate patients and healthcare providers about the benefits of alternative therapies and regenerative medicine in comparison to standard or more invasive treatment options.
Company Details
- Founded
- -
- Address
- 800 Park Offices Drive,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Research Triangle Park, NC
Opticyte Questions
Opticyte's website is https://merakris.com/ocular-therapeutics/
Opticyte's LinkedIn profile is https://www.linkedin.com/company/opticyte-amniotic-matrix-and-tears
Opticyte's industry is
Biotechnology Research
Opticyte's top competitors are
Tempus Ai,
Velocity Clinical Research, Inc.,
Clinsocial,
Ocular Therapeutix, Inc.,
Site Recruitment Ltd,
Veracyte, Inc.,
Cytovale,
Parexel,
Clinmastery,
Opticyte.
Opticyte's categories are Biotechnology Research
Opticyte's founding year is 2016
